BioCryst Pharma (BCRX) Tops Q2 EPS by 14c

BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of $0.30, $0.14 better than the analyst estimate of $0.16. Revenue for the quarter came in at $218.3 million versus the consensus estimate of $185.69 million.

Financial Outlook for 2026

The company maintained its outlook for full year 2026 global net ORLADEYO revenue of $625 million to $645 million. The company raised the full year 2026 total revenue outlook, including RAPIVAB® (peramivir injection) and revenue from the licensing of navenibart European rights, to $690 million to $715 million.

In June, the company improved its outlook for full year 2026 non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs, to $420 million to $440 million, due to the announced plans to discontinue internal discovery programs and close the Birmingham facility.

Item As of August 5, 2026 As of May 6, 2026
ORLADEYO revenue Unchanged $625 million to $645 million
Total revenue $690 million to $715 million $635 million to $660 million
Non-GAAP operating expense $420 million to $440 million $450 million to $470 million

Conference Call and Webcast

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• Avnet (AVT) Tops Q4 EPS by 61c; offers guidance
• Icahn Enterprises L.P. (IEP) Misses Q2 EPS by 64c
• Erste Group Upgrades salesforce.com (CRM) to Buy